[Checkpoint inhibitor-induced myocarditis]

Area of Science:

• Oncology
• Immunology
• Cardiology

Context:

• Immune checkpoint inhibitors (ICIs) are a revolutionary cancer therapy.
• Myocarditis is a rare but serious adverse effect of ICIs.
• The incidence of ICI-induced myocarditis is rising with increased ICI use.

Purpose:

• To provide a clinical review of immune checkpoint inhibitor-induced myocarditis.
• To highlight the importance of early diagnosis and treatment.
• To inform healthcare professionals about this adverse event.

Summary:

• This review covers the clinical aspects of myocarditis associated with immune checkpoint inhibitors.
• It discusses the increasing prevalence and significance of this adverse effect in cancer patients.
• Key information for timely recognition and management is presented.

Impact:

• Facilitates earlier detection and intervention for myocarditis in cancer patients undergoing ICI therapy.
• Enhances the understanding of a critical adverse event in immuno-oncology.
• Aims to improve patient outcomes by addressing cardiac complications of cancer treatment.